CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
19 12월 2023 - 9:00PM
Business Wire
CareDx Expands Reach of its Transplant Pharmacy
Services by Offering NFT Patients Help in Navigating the Complexity
of Immunosuppression Medications and Adherence
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – today announced that it is joining forces
with the National Foundation for Transplants (NFT) in offering its
Transplant Pharmacy services to NFT patient members to help them
manage the complexity of post-transplant medication adherence.
Medication regimens for organ transplant patients are highly
complex, and non-adherence is one of the leading causes of organ
transplant graft loss. NFT will be introducing CareDx’s Transplant
Pharmacy services to its broad network including thousands of
transplant patients.
“CareDx is proud to collaborate with the National Foundation for
Transplants, a group that shares our mission to improve the
transplant patient journey and access to life-saving organs,” said
Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.
“Our Transplant Pharmacy team looks forward to serving more
patients by expanding its reach to NFT’s membership and providing
them with greater support in adhering to complex medication
schedules once they’ve been given the precious gift of life.”
CareDx’s Transplant Pharmacy team provides individualized
transplant pharmacy services for patients at multiple transplant
centers located throughout the United States. Dedicated to patient
care and medication adherence, the pharmacy coordinates benefits to
reduce out-of-pocket costs and ensures patients receive
personalized care with regular touch points.
“We look forward to working with CareDx as we advocate for
transplant patients and the thousands of people on organ transplant
waiting lists,” said Jared Wall, President, and CEO of National
Foundation for Transplants. “Our goal is to ensure nothing stands
in the way of a patient’s chance to receive lifesaving care, and we
believe that CareDx's Transplant Pharmacy services will help our
patients navigate one of the biggest challenges facing transplant
patients—medication access, education, and adherence.”
About The National Foundation for Transplants
The National Foundation for Transplants focuses on providing
fundraising expertise and advocacy for transplant patients, being a
program resource for medical professionals, promoting organ and
tissue donation, and supporting innovative solutions and lifesaving
treatments. Since 1983, the National Foundation for Transplants has
generated $82 million in fundraising and support for more than
4,000 transplant patients every year. Learn more at
https://transplants.org/.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
benefits and results that may be achieved with CareDx’s
collaboration with the National Foundation for Transplants (the
“Collaboration”). These forward-looking statements are based upon
information that is currently available to CareDx and its current
expectations, speak only as of the date hereof, and are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected, including risks that CareDx does
not realize the expected benefits of the Collaboration; general
economic and market factors; and other risks discussed in CareDx’s
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2022 filed by CareDx with the
SEC on February 27, 2023, the quarterly report on Form 10-Q for the
quarter ended March 31, 2023 filed by CareDx with the SEC on May
10, 2023, the quarterly report on Form 10-Q for the quarter ended
June 30, 2023 filed by CareDx with the SEC on August 8, 2023, the
quarterly report on Form 10-Q for the quarter ended September 30,
2023 filed by CareDx with the SEC on November 8, 2023, and other
reports that CareDx has filed with the SEC. Any of these may cause
CareDx’s actual results, performance, or achievements to differ
materially and adversely from those anticipated or implied by
CareDx’s forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231219379430/en/
Media Relations Anna Czene 818-731-2203 aczene@caredx.com
Investor Relations Greg Chodaczek Investor@caredx.com
CareDx (NASDAQ:CDNA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
CareDx (NASDAQ:CDNA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024